Sandoz reaches further settlement in the USA
Keystone-SDA
The Swiss generic drugs manufacturer Sandoz has agreed to pay more than $500 million to settle legacy United States anti-trust legal issues.
+Get the most important news from Switzerland in your inbox
Sandoz has reached a settlement agreement with the class of final claimants for $275 million, according to a statement on Tuesday. In addition, provisions of $265 million have been set aside to cover potential further settlement costs for antitrust proceedings in the US generics industry.
These measures have no impact on the current annual forecast or the medium-term targets, it added. In recent years, Sandoz has gradually cleared up its legal legacy. The Group had already reached settlements with the US Department of Justice in 2020 and 2021. Then, in February of this year, with the plaintiff group of direct purchasers.
The settlement now announced with the class of ultimate purchasers, which includes consumers, insurers and social insurance companies, is expected to be paid before December 31, 2024. According to the information provided, the settlement still has to be approved by the court.
Translated from German by DeepL/mga
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
